AI YOSEMITE, LLC
AI YOSEMITE, LLC is a Seed, Series A, Series B and Series C+ fund in the US investing in Healthcare, oncology and drug-discovery.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- Healthcare, oncology, drug-discovery
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2023
- Assets under management
- $1B+
Check size not disclosed
Thesis
The firm is dedicated to making cancer non-lethal by investing in companies and researchers focused on oncology. Yosemite employs a dual model, providing for-profit investments in early-stage companies and philanthropic grants to academic researchers. Their investment thesis targets breakthrough companies in areas like AI-powered drug discovery and novel antibody-drug conjugates, primarily at the seed to Series B stages. They also incubate companies from academic partners and internal ideation. Yosemite manages over $1 billion in AUM, with its second fund targeting $350 million and having closed on $200 million, following a $263 million debut fund in 2024. The firm expects to invest in 20-25 companies with its second fund. Yosemite's geographic focus is primarily the United States.
Common questions
Does AI YOSEMITE, LLC invest at the Seed stage?
Yes. AI YOSEMITE, LLC lists Seed, Series A, Series B and Series C+ among the stages it invests in.
Where does AI YOSEMITE, LLC invest?
AI YOSEMITE, LLC invests in the US.